Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its stake in shares of Immatics (NASDAQ:IMTX) by 7.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 299,066 shares of the company’s stock after selling 22,694 shares during the period. JPMorgan Chase & Co. owned 0.25% of Immatics worth $3,412,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in shares of Immatics in the second quarter valued at $321,000. HighVista Strategies LLC acquired a new stake in shares of Immatics during the 2nd quarter worth about $904,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Immatics during the 2nd quarter worth about $2,404,000. The Manufacturers Life Insurance Company grew its holdings in shares of Immatics by 13.9% during the second quarter. The Manufacturers Life Insurance Company now owns 150,769 shares of the company’s stock worth $1,752,000 after buying an additional 18,354 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in shares of Immatics in the second quarter valued at approximately $13,392,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Analyst Ratings Changes

IMTX has been the subject of several analyst reports. The Goldman Sachs Group upgraded Immatics to a “strong-buy” rating in a report on Monday, November 25th. Piper Sandler began coverage on Immatics in a research report on Monday, October 7th. They set an “overweight” rating and a $19.00 target price on the stock. Finally, Bank of America lowered their price target on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Immatics currently has an average rating of “Buy” and a consensus target price of $16.67.

Immatics Stock Up 0.2 %

IMTX stock opened at $5.35 on Friday. The company has a market cap of $638.58 million, a price-to-earnings ratio of -8.11 and a beta of 0.77. The business has a fifty day simple moving average of $7.35 and a 200-day simple moving average of $9.85. Immatics has a 52 week low of $5.28 and a 52 week high of $13.77.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.